Literature DB >> 19251210

Color-coded three-dimensional entrainment mapping for analysis and treatment of atrial macroreentrant tachycardia.

Masahiro Esato1, Gerhard Hindricks, Philipp Sommer, Arash Arya, Thomas Gaspar, Kerstin Bode, Andreas Bollmann, Ulrike Wetzel, Sebastian Hilbert, Simon Kircher, Charlotte Eitel, Christopher Piorkowski.   

Abstract

BACKGROUND: Mapping and ablation of atrial macroreentrant tachycardia focus on activation mapping with identification of the area of slow conduction.
OBJECTIVE: The purpose of this study was to evaluate a new concept for analysis and treatment of macroreentrant tachycardia based on color-coded three-dimensional (3D) entrainment mapping and subsequent placement of strategic lesion lines.
METHODS: Twenty-six patients presented with macroreentrant tachycardia (cycle length 329 +/- 70 ms). Using nonfluoroscopic systems (CARTO 12, NavX 14), sequential mapping of the target atrium was performed. On each mapping point, the 3D location was paired with color-coded entrainment information so that the reentrant circuit could be directly visualized.
RESULTS: Procedural duration, fluoroscopy time, and radiofrequency time measured 181 +/- 58, 37 +/- 19, and 31 +/- 17 minutes, respectively. Thirty-nine macroreentrant tachycardias were ablated: perimitral 9, around pulmonary vein ostium 6, through left atrial roof 5, around left atrial appendage 3, right atrial cavotricuspid isthmus dependent 6, around right atrial scar 2, around superior vena cava 1, within the septum 5, and within the coronary sinus 2. Tachycardia termination and noninducibility of any macroreentrant tachycardia was the procedural end-point. In case of left atrial macroreentrant tachycardia, pulmonary vein isolation was completed. Follow-up with serial 7-day Holter covered 302 +/- 82 days. Two (8%) patients experienced recurrences of a pretreated macroreentrant tachycardia.
CONCLUSION: In patients with macroreentrant tachycardia, color-coded 3D entrainment mapping is feasible to accurately determine and visualize the 3D location of the reentrant circuit and to plan a strategic ablation line concept. That approach, not targeting the area of slow conduction of the circuit, resulted in excellent procedural success (100%), with long-term freedom from any tachycardia recurrences in 88% of patients.

Entities:  

Mesh:

Year:  2008        PMID: 19251210     DOI: 10.1016/j.hrthm.2008.12.013

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  9 in total

1.  Spontaneous left atrial reentry tachycardias : radiofrequency ablation and outcome.

Authors:  R Schneider; C Schneider; D Bänsch
Journal:  Herz       Date:  2013-08-03       Impact factor: 1.443

2.  Comparison between novel and standard high-density 3D electro-anatomical mapping systems for ablation of atrial tachycardia.

Authors:  Philippe Maury; Laure Champ-Rigot; Anne Rollin; Pierre Mondoly; Vanina Bongard; Michel Galinier; Didier Carrié; Emilie Marminia; Stefano Capellino; Lilian Marty; Paul Milliez
Journal:  Heart Vessels       Date:  2018-11-19       Impact factor: 2.037

Review 3.  2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design.

Authors:  Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; Jose Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber
Journal:  J Interv Card Electrophysiol       Date:  2012-03       Impact factor: 1.900

4.  Clinical significance of induced left atrial macro-reentrant tachycardia after pulmonary vein isolation.

Authors:  Hideyuki Hara; Masahiro Yoshinaga; Yumie Matsui; Satoshi Yamamoto; Takahiro Ishido; Kotaro Yutaka; Tomonori Kasuu; Masahiro Karakawa
Journal:  J Interv Card Electrophysiol       Date:  2015-09-21       Impact factor: 1.900

Review 5.  Procedural Feasibility and Long-Term Efficacy of Catheter Ablation of Atypical Atrial Flutters in a Wide Spectrum of Heart Diseases: An Updated Clinical Overview.

Authors:  Roberto De Ponti; Raffaella Marazzi; Manola Vilotta; Fabio Angeli; Jacopo Marazzato
Journal:  J Clin Med       Date:  2022-06-09       Impact factor: 4.964

Review 6.  Electroanatomical mapping of atrial fibrillation: Review of the current techniques and advances.

Authors:  Sascha Rolf; Gerhard Hindricks; Philipp Sommer; Sergio Richter; Arash Arya; Andreas Bollmann; Jedrzej Kosiuk; Emmanuel Koutalas
Journal:  J Atr Fibrillation       Date:  2014-12-31

7.  Role of the coronary sinus ostium musculature in reentrant formation.

Authors:  Y Huo; A Arya; T Gaspar; S Richter; R Schoenbauer; P Sommer; A Bollmann; G Hindricks; C Piorkowski
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-06

8.  Contemporary Mapping Techniques of Complex Cardiac Arrhythmias - Identifying and Modifying the Arrhythmogenic Substrate.

Authors:  Emmanuel Koutalas; Sascha Rolf; Borislav Dinov; Sergio Richter; Arash Arya; Andreas Bollmann; Gerhard Hindricks; Philipp Sommer
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-03-10

9.  The APPLE Score - A Novel Score for the Prediction of Rhythm Outcomes after Repeat Catheter Ablation of Atrial Fibrillation.

Authors:  Jelena Kornej; Gerhard Hindricks; Arash Arya; Philipp Sommer; Daniela Husser; Andreas Bollmann
Journal:  PLoS One       Date:  2017-01-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.